SALT LAKE CITY--(BUSINESS WIRE)--
BSD Medical Corporation (BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that the Company has received a significant purchase order for MicroThermX Microwave Ablation (MicroThermX) products from its exclusive distributor in Egypt, Misr Sinai Company (MCS). MCS is a leading medical specialty distributor in Egypt headquartered in Cairo.
"MCS has a total staff of 120 employees. All of the MCS sales representatives are either physicians or biomedical engineers," said Sam Maravich, Vice President of International Sales and Marketing for BSD. "MCS prides itself on its professional, effective sales force and represents several products in the oncology market. MCS sells numerous products to the same physicians targeted for the MicroThermX, which fits well with BSD’s strategy to continue expanding our worldwide MicroThermX user base."
About the MicroThermX Microwave Ablation System
The MicroThermX is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermXis the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermXutilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermXintroduces into the Company’s product line innovative, high-end disposables (SynchroWave antennas) that are used in each ablation treatment and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX System, which allows BSD to market the MicroThermXin Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermXto a number of international markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s MicroThermX microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.
- Health Care Industry
- Consumer Discretionary
William (Bill) S. Barth, 801-972-5555